Advertisement

Sadness/Demoralisation and Apathy

  • Angelo Picardi
  • Paola Gaetano
  • Elisa Fabi
Chapter

Abstract

The Sadness/Demoralisation dimension concerns core depressive symptoms that have long been the subject of clinical discussion. In fact, they have been described as key features of depression in ancient Greek medical texts. They are believed to result from functional abnormalities in cortical and subcortical regions involved in emotion regulation and reward processing. Besides deficiencies in noradrenergic and serotonergic function, other contributing neurobiological factors have been proposed (e.g. deficits in other neurotransmitters and neurotrophic factors, altered hippocampal neurogenesis, HPA dysregulation, and inflammation). This dimension displays a “cross-nosological” character, as it is often prominent in patients with diagnoses other than depressive disorders. Its neurobiology suggests treatment through the use of agents enhancing brain noradrenergic or serotonergic transmission, along with other agents and interventions. There are several effective psychotherapeutic treatments, which lead to observable changes in the brain. Antidepressants and psychotherapy may have distinct neural effects. Their combination seems to have some advantages.

Apathy partially overlaps with depression, although it is considered a distinct construct. It also shows considerable overlap with the negative symptom domain of schizophrenia. Lesion-based and imaging data suggest that frontal-subcortical circuits involving the prefrontal cortex and basal ganglia are implicated in the neurobiology of Apathy. Among the neurotransmitters, dopamine has been the most researched, although others are likely involved. In depression, Apathy symptoms may respond poorly to serotonergic medication. Antidepressants that enhance catecholaminergic activity may offer some advantages. If response is poor, dopaminergic agents may be considered. Psychotherapy, particularly behavioural activation, may also be useful. In schizophrenia, Apathy poses severe challenges, as it is difficult to bring about substantial improvement in negative symptoms with any treatment.

Keywords

Depression Anhedonia Apathy Neurobiology Medication Psychotherapy Personalised Treatment 

References

  1. 1.
    Burton R. The anatomy of melancholy. New York, NY: The New York Review of Books; 2001.Google Scholar
  2. 2.
    Horwitz AV, Wakefield JC, Lorenzo-Luaces L. History of depression. In: Derubeis RJ, Strunk DR, editors. The Oxford handbook of mood disorders. New York: Oxford University Press; 2017.Google Scholar
  3. 3.
    Kendler KS. The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry. 2016;173:771–80.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Pancheri P, Picardi A, Pasquini M, Gaetano P, Biondi M. Psychopathological dimensions of depression: a factor study of the 17-item Hamilton depression rating scale in unipolar depressed outpatients. J Affect Disord. 2002;68:41–7.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol. 2006;62:123–46.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Biondi M, Picardi A, Pasquini M, Gaetano P, Pancheri P. Dimensional psychopathology of depression: detection of an ‘activation’ dimension in unipolar depressed outpatients. J Affect Disord. 2005;84:133–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100:316–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Anderson ER, Hope DA. A review of the tripartite model for understanding the link between anxiety and depression in youth. Clin Psychol Rev. 2008;28:275–87.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. J Abnorm Psychol. 1995;104:15–25.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161–70.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Bech P, Cialdella P, Haugh M, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 2000;176:421–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry. 2010;43:271–6.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Binswanger L. Melancholie und Manie. Phänomenologische Studien Pfullingen. Germany: Verlag Günther Neske; 1960.Google Scholar
  14. 14.
    Le ME. temps vécu. Etudes phénoménologiques et psychopathologiques. Paris: D’Artrey; 1933.Google Scholar
  15. 15.
    Tatossian A. Phénoménologie des psychoses. Paris: Masson; 1979.Google Scholar
  16. 16.
    Ratcliffe M. Experiences of depression: a study in phenomenology. New York: Oxford University Press; 2015.Google Scholar
  17. 17.
    Picardi A, Pallagrosi M, Fonzi L, Biondi M. Psychopathological dimensions and the clinician’s subjective experience. Psychiatry Res. 2017;258:407–14.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Frank JD. Psychotherapy. The restoration of morale. Am J Psychiatr. 1974;131:271–4.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Aust N Z J Psychiatry. 2002;36:733–42.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    De Figueiredo JM. Distress, demoralization and psychopathology: diagnostic boundaries. Eur J Psychiatry. 2013;27:61–73.CrossRefGoogle Scholar
  21. 21.
    Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical characterization. Psychol Med. 2015;45:673–91.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    De Figueiredo JM. Depression and demoralization: phenomenological differences and research perspectives. Compr Psychiatry. 1993;34:308–11.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Willner P, Scheel-Krüger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev. 2013;37:2331–71.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev. 2009;33:699–771.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T, Trivedi MH. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry. 2015;172:124–38.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014;10:393–423.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(Suppl 6):4–6.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Mahar I, Rodriguez Bambico F, Mechawar N, Nobrega JN. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev. 2014;38:173–92.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–41.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat. 2014;71:1381–91.CrossRefGoogle Scholar
  35. 35.
    Lavebratt C, Herring MP, Liu JJ, Wei YB, Bossoli D, Hallgren M, Forsell Y. Interleukin-6 and depressive symptom severity in response to physical exercise. Psychiatry Res. 2017;252:270–6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Lieverse R, Van Someren EJ, Nielen MM, Uitdehaag BM, Smit JH, Hoogendijk WJ. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2011;68:61–70.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Perera S, Eisen R, Bhatt M, Bhatnagar N, de Souza R, Thabane L, Samaan Z. Light therapy for non-seasonal depression: systematic review and meta-analysis. BJPsych Open. 2016;2:116–26.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, Jonas DE, Swinson Evans T, Viswanathan M, Lohr KN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75:477–89.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Noda Y, Silverstein WK, Barr MS, Vila-Rodriguez F, Downar J, Rajji TK, Fitzgerald PB, Mulsant BH, Vigod SN, Daskalakis ZJ, Blumberger DM. Neurobiological mechanisms of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex in depression: a systematic review. Psychol Med. 2015;45:3411–32.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci. 2011;13:139–45.PubMedPubMedCentralGoogle Scholar
  41. 41.
    UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808.CrossRefGoogle Scholar
  42. 42.
    Loo C, Katalinic N, Mitchell PB, Greenberg B. Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. J Affect Disord. 2011;132:1–13.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Leroy A, Naudet F, Vaiva G, Francis A, Thomas P, Amad A. Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2017. [Epub ahead of print].  https://doi.org/10.1007/s00406-017-0819-5.
  44. 44.
    Grover S, Kumar Mattoo S, Gupta N. Theories on mechanism of action of electroconvulsive therapy. German. J Psychiatry. 2005;8:70–84.Google Scholar
  45. 45.
    Fosse R, Read J. Electroconvulsive treatment: hypotheses about mechanisms of action. Front Psych. 2013;4:94.Google Scholar
  46. 46.
    Merkl A, Heuser I, Bajbouj M. Antidepressant electroconvulsive therapy: mechanism of action, recent advances and limitations. Exp Neurol. 2009;219:20–6.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Scott A. Mode of action of electroconvulsive therapy: an update. Adv Psychiatr Treat. 2011;17:15–22.CrossRefGoogle Scholar
  48. 48.
    Picardi A, Gaetano P. Psychotherapy of mood disorders. Clin Prac Epidemiol Ment Health. 2014;10:140–58.CrossRefGoogle Scholar
  49. 49.
    Freud S. Project for a scientific psychology. In: Strachey J, editor. Standard edition of the complete psychological works of Sigmund Freud, vol. 1. London: Hogarth Press; 1895/1966. p. 283–397.Google Scholar
  50. 50.
    Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry. 1998;155:457–69.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Linden DE. How psychotherapy changes the brain–the contribution of functional neuroimaging. Mol Psychiatry. 2006;11:528–38.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Beauregard M. Functional neuroimaging studies of the effects of psychotherapy. Dialogues Clin Neurosci. 2014;16:75–81.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Barsaglini A, Sartori G, Benetti S, Pettersson-Yeo W, Mechelli A. The effects of psychotherapy on brain function: a systematic and critical review. Prog Neurobiol. 2014;114:1–14.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Weingarten CP, Strauman TJ. Neuroimaging for psychotherapy research: current trends. Psychother Res. 2015;25:185–213.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Dichter GS, Felder JN, Petty C, Bizzell J, Ernst M, Smoski MJ. The effects of psychotherapy on neural responses to rewards in major depression. Biol Psychiatry. 2009;66:886–97.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Fournier JC, Price RB. Psychotherapy and neuroimaging. Focus. 2014;12:290–8.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Quidé Y, Witteveen AB, El-Hage W, Veltman DJ, Olff M. Differences between effects of psychological versus pharmacological treatments on functional and morphological brain alterations in anxiety disorders and major depressive disorder: a systematic review. Neurosci Biobehav Rev. 2012;36:626–44.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Boccia M, Piccardi L, Guariglia P. How treatment affects the brain: meta-analysis evidence of neural substrates underpinning drug therapy and psychotherapy in major depression. Brain Imaging Behav. 2016;10:619–27.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Busch FN, Sandberg LS. Combined treatment of depression. Psychiatr Clin North Am. 2012;35:165–79.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70:1219–29.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26:279–88.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Cuijpers P, van Straten A, Hollon SD, Andersson G. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Acta Psychiatr Scand. 2010;121:415–23.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Guidi J, Fava GA, Fava M, Papakostas GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in majordepressive disorder: a preliminary meta-analysis. Psychol Med. 2011;41:321–31.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Biondi M. Beyond the brain-mind dichotomy and toward a common organizing principle of pharmacological and psychological treatments. Psychother Psychosom. 1995;64:1–8.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Picardi A, Biondi M. Towards an integrated treatment of depression. Riv Psichiatr. 2002;37:284–9.Google Scholar
  66. 66.
    Pasquini M, Picardi A, Biondi M, Scarciglia P, Pancheri P. Analisi Psicopatologica Dimensionale del Disturbo Ossessivo-Compulsivo: appartiene realmente ai Disturbi d’Ansia? Riv Psichiatr. 2003;38(2):86–91.Google Scholar
  67. 67.
    Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342–51.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Wiethoff K, Bauer M, Baghai TC, Möller HJ, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Brieger P, Kronmüller KT, Zeiler J, Adli M. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German algorithm project. J Clin Psychiatry. 2010;71:1047–54.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and Psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32:549–75.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Ionescu DF, Niciu MJ, Richards EM, Zarate CA. Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord. 2014;16(3).  https://doi.org/10.4088/PCC.13r01621.
  71. 71.
    De la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: structural and functional analysis. Prog Neurobiol. 2010;90:198–216.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Markowitz JC, Lipsitz J, Milrod BL. Critical review of outcome research on interpersonal psychotherapy for anxiety disorders. Depress Anxiety. 2014;31:316–25.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Smits JA, Hofmann SG. A meta-analytic review of the effects of psychotherapy control conditions for anxiety disorders. Psychol Med. 2009;39:229–39.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P. Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? Depress Anxiety. 2011;28:560–7.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Carey TA. Exposure and reorganization: the what and how of effective psychotherapy. Clin Psychol Rev. 2011;31:236–48.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Picardi A, Morosini P, Gaetano P, Pasquini M, Biondi M. Higher levels of anger and aggressiveness in unipolar depression as compared with anxiety and somatoform disorders. J Clin Psychiatry. 2004;65:442–3.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Piacentino D, Pasquini M, Tarsitani L, Berardelli I, Roselli V, Maraone A, Biondi M. The association of anger with symptom subtypes in severe obsessive-compulsive disorder outpatients. Psychopathology. 2016;49:40–6.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Olivier B. Serotonin and aggression. Ann N Y Acad Sci. 2004;1036:382–92.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Yanowitch R, Coccaro EF. The neurochemistry of human aggression. Adv Genet. 2011;75:151–69.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Duke AA, Bègue L, Bell R, Eisenlohr-Moul T. Revisiting the serotonin-aggression relation in humans: a meta-analysis. Psychol Bull. 2013;139:1148–72.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Coccaro EF, Fanning JR, Phan KL, Lee R. Serotonin and impulsive aggression. CNS Spectr. 2015;20:295–302.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135–53.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. Int J Bipolar Disord. 2015;3:32.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Pasquini M, Picardi A, Speca A, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: open study. Clin Pract Epidemol Ment Health. 2007;3:3–4.CrossRefGoogle Scholar
  85. 85.
    Paris J. Clinical trials of treatment for personality disorders. Psychiatr Clin North Am. 2008;31:517–26.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Bateman A, Fonagy P. Mentalization based treatment for borderline personality disorder. World Psychiatry. 2010;9:11–5.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Bear RA, Nietzel MT. Cognitive and behavioral treatment of impulsivity in children: a meta-analytic review of the outcome literature. J Clin Child Psychol. 1991;20:400–12.CrossRefGoogle Scholar
  88. 88.
    Lee AH, DiGiuseppe R. Anger and aggression treatments: a review of meta-analyses. Curr Opin Psychol. 2017;19:65–74.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. New York: Guilford; 2002.Google Scholar
  90. 90.
    Amutio A, Franco C, Pérez-Fuentes Mde C, Gázquez JJ, Mercader I. Mindfulness training for reducing anger, anxiety, and depression in fibromyalgia patients. Front Psychol. 2014;5:1572.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015;16:213–25.CrossRefGoogle Scholar
  92. 92.
    Linehan MM, Wilks CR. The course and evolution of dialectical behavior therapy. Am J Psychother. 2015;69:97–110.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Guidano VF. The self in process. New York: Guilford Press; 1991.Google Scholar
  94. 94.
    Gaetano P, Maselli P, Meldolesi GN, Picardi A. Experience-centred cognitive psychotherapy: towards a phenomenologically oriented therapy. Riv Psichiatr. 2015;50:51–60.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Enright RD, Fitzgibbons RP. Helping clients forgive: an empirical guide for resolving anger and restoring hope. Washington, DC: American Psychological Association Books; 2000.CrossRefGoogle Scholar
  96. 96.
    Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res. 1991;38:143–62.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Marin RS, Firinciogullari S, Biedrzycki RC. The sources of convergence between measures of apathy and depression. J Affect Disord. 1993;28:117–24.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10:314–9.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Kirsch Darrow L, Fernandez HF, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67:33–8.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Pedersen KF, Larsen JP, Alves G, Aarslan D. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord. 2009;5:95–9.Google Scholar
  101. 101.
    Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different construct? A critical review. Arch Gerontol Geriatr. 2009;49:246–9.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Starkstein SE, Leentjens AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79:1088–92.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147:22–30.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Marin RS, Frinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994;182:235–9.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci. 2005;17:7–19.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, Caci H, Borg M, Brocker P, Bedoucha P. The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17:1099–105.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Sockeel P, Dujardin K, Devos D, Deneve C, Desèe A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:579–84.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Clarke DE, Ko JY, Kuhl EA, Van Reekum R, Salvador R, Marin RS. Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res. 2011;70:73–97.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Weiss HD, Marsh L. Apathy in Parkinson’s disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M, editors. Parkinson’s disease. 2nd ed. Boca Raton: CRC Press; 2012.Google Scholar
  110. 110.
    Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16:916–28.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J Am Geriatr Soc. 2001;49:1700–7.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238–45.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–92.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009 Mar;24(2):98–104.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry. 2001;158(6):872–7.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Mulin E, Leone E, Dujardin K, Delliaux M, Leentjens A, Nobili F, Dessi B, Tible O, Agüera-Ortiz L, Osorio RS, Yessavage J, Dachevsky D, Verhey FR, Cruz Jentoft AJ, Blanc O, Llorca PM, Robert PH. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry. 2011 Feb;26(2):158–65.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Stuss DT, Van Reekum R, Murphy KJ. Differentiation of states and causes of apathy. In: Borod JC, editor. The neuropsychology of emotion. New York: Oxford University Press; 2000. p. 340–63.Google Scholar
  118. 118.
    Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res. 2002;53:647–54.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Theleritis C, Politis A, Siarkos K, Lyketsos CG. A review of neuroimaging findings of apathy in Alzheimer’s disease. Int Psychogeriatr. 2014;26:195–207.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Alexopoulos GS, Hoptman MJ, Yuen G, Kanellopoulos D, Seirup JK, Lim KO, Gunning FM. Functional connectivity in apathy of late-life depression: a preliminary study. J Affect Disord. 2013 Jul;149(1–3):398–405.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Doubois B. Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia. 2002;40:2257–67.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Muhammed K, Manohar S, Lennox G, Ben Yehuda M, Chong TT, Tofaris G, et al. Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's disease. Brain. 2016;139:2706–21.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Roth RM, Flashman LA, McAllister TW. Apathy and its treatment. Curr Treat Options Neurol. 2007 Sep;9(5):363–70.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Robinson RG, Jorge RE, Clarence-Smith K, et al. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009;21(2):144–51.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Chaturvedi SK, Sarmukaddam SB. Prediction of outcome in depression by negative symptoms. Acta Psychiatr Scand. 1986;74:183–6.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Levkovitz Y, Sheer A, Harel EV, Katz LN, Most D, Zangen A, Isserles M. Differential effects of deep TMS of the prefrontal cortex on apathy and depression. Brain Stimul. 2011 Oct;4(4):266–74.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004;10:196–9.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7(10):14–8.Google Scholar
  129. 129.
    Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine andfluoxetine. J Clin Psychopharmacol. 1990;10:343–5.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Hoehn-Saric R, Harris GJ, Pearlson GD, et al. A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry. 1991;52:131–3.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Reinblatt SP, Riddle MA. Selective sero- tonin reuptake inhibitor-induced apathy: a pediatric case series. J Child Adolesc Psychopharmacol. 2006;16:227–33.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001;11:181–6.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Sato S, Asada T. Sertraline-induced apathy syndrome. J Neuropsychiatry Clin Neurosci. 2011;23:E19.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Kodela S, Venkata PD. Antidepressant induced apathy responsive to dose reduction. Psychopharmacol Bull. 2010;43:76–9.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH. Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother. 2012;46(3):e8.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotoninreuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195:211–7.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom. 2004;73:380–5.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67(11):1754–9.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5:147–51.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann General Psychiatry. 2007;6:7.CrossRefGoogle Scholar
  141. 141.
    Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–5.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Zald DH, Depue RA. Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males. Pers Individ Dif. 2001;30:71–86.CrossRefGoogle Scholar
  143. 143.
    Blier P, Briley M. The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatr Dis Treat. 2011;7(1):15–20.PubMedPubMedCentralGoogle Scholar
  144. 144.
    McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67(5):439–45.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco JL, Stahl S. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461–71.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol. 1997;7(1):S49–55.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Raskin J, George T, Granger RE, Hussain N, Zhao GW, Marangell LB. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. J Psychiatr Res. 2012;46:667–74.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–48.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159–66.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7:89–91.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172:561–9.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Ciraulo DA, Shader RI, Greenblatt DJ. Clinical pharmacology and therapeutics of antidepressants. In: Ciraulo DA, Shader RI, editors. Pharmacotherapy of depression. 2nd ed. New York: Humana Press; 2011. p. 33–124.CrossRefGoogle Scholar
  153. 153.
    Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477–502.PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther. 2015;153:135–47.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry. 2016;3:133–50.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Kapur S. How antipsychotics become anti-“psychotic” – from dopamine to salience to psychosis. Trends Pharmacol Sci. 2004;25(8):402–6.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebocontrolled study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1879–83.CrossRefGoogle Scholar
  158. 158.
    Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL. Ritanserin a selective 5- HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry. 1993;163:451–5.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47:472–8.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacol (Berl). 2013;228:595–602.CrossRefGoogle Scholar
  161. 161.
    Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–9.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil. 2005;20:377–88.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Kumari V, Fannon D, Peters ER, Ffytche DH, Sumich AL, Premkumar P, Anilkumar AP, Andrew C, Phillips ML, Williams SC, Kuipers E. Neural changes following cognitive behaviour therapy for psychosis: a longitudinal study. Brain. 2011 Aug;134(Pt 8):2396–407.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini A, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M. Italian network for research on psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13:275–87.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Behavioural Sciences and Mental HealthItalian National Institute of HealthRomeItaly
  2. 2.Italian Society of Cognitive and Behavioural TherapyRomeItaly
  3. 3.Department of Human NeurosciencesSapienza University of RomeRomeItaly

Personalised recommendations